Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

about

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia

P2860

Q57191729-E32D7AC4-5274-4BD8-B9DB-9E9AB9370DE5 Q58793756-0A965014-452F-45A0-820D-96A946B45CDB

P2860

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

Item

http://www.wikidata.org/entity/Q47203479

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

@en

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

@nl

type

Item

label

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

@en

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

@nl

prefLabel

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

@en

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

@nl

P1476

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

@en

P2093

Brent L Wood

http://www.w3.org/2001/XMLSchema#string

David M Barrett

http://www.w3.org/2001/XMLSchema#string

David T Teachey

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Raetz

http://www.w3.org/2001/XMLSchema#string

Karen L Bride

http://www.w3.org/2001/XMLSchema#string

Kimberly P Dunsmore

http://www.w3.org/2001/XMLSchema#string

Meenakshi Devidas

http://www.w3.org/2001/XMLSchema#string

Michelle L Hermiston

http://www.w3.org/2001/XMLSchema#string

Mignon L Loh

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

P2860

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

P31

scholarly article

P356

10.1182/BLOOD-2017-07-794214

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Stephen P Hunger

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29305553

http://www.w3.org/2001/XMLSchema#string

P932

5833263

http://www.w3.org/2001/XMLSchema#string

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

about

P2860

P2860

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932